These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20606660)

  • 21. [Proton pump inhibitors, a family of drugs in continuous expansion].
    Pellicano R
    Minerva Gastroenterol Dietol; 2000 Dec; 46(4):231-41. PubMed ID: 19320085
    [No Abstract]   [Full Text] [Related]  

  • 22. Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.
    Garrean CP; Zhang Q; Gonsalves N; Hirano I
    Am J Gastroenterol; 2008 Jul; 103(7):1631-7. PubMed ID: 18557714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
    Inadomi JM; McIntyre L; Bernard L; Fendrick AM
    Am J Gastroenterol; 2003 Sep; 98(9):1940-4. PubMed ID: 14499769
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rebound acid hypersecretion.
    Porro GB
    Scand J Gastroenterol; 2010 Apr; 45(4):387-8. PubMed ID: 20302534
    [No Abstract]   [Full Text] [Related]  

  • 25. Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?
    Bruley des Varannes S; Coron E; Galmiche JP
    Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):905-21. PubMed ID: 21126703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children.
    Lee JH; Kim MJ; Lee JS; Choe YH
    Arch Dis Child; 2011 Jan; 96(1):9-13. PubMed ID: 20870626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexlansoprazole MR: a review.
    Hershcovici T; Jha LK; Fass R
    Ann Med; 2011 Aug; 43(5):366-74. PubMed ID: 21366513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Gastroesophageal reflux disease and dyspepsia--drug therapy].
    Gräter H
    Praxis (Bern 1994); 2006 Aug; 95(31-32):1179-83. PubMed ID: 16909686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior helicobacter pylori eradication therapy in gastric ulcer patients: a randomized prospective study.
    Wada Y; Ito M; Takata S; Kitamura S; Takamura A; Tatsugami M; Imagawa S; Matsumoto Y; Tanaka S; Yoshihara M; Chayama K
    Hepatogastroenterology; 2009; 56(91-92):624-8. PubMed ID: 19621668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat.
    McColl KE; Gillen D
    Gastroenterology; 2009 Jul; 137(1):20-2. PubMed ID: 19482105
    [No Abstract]   [Full Text] [Related]  

  • 31. Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive?
    Namikawa K; Björnsson ES
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse.
    Reimer C; Bytzer P
    Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1182-8. PubMed ID: 20664352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Primary care for GEDR].
    Takeda H
    Nihon Rinsho; 2004 Aug; 62(8):1499-503. PubMed ID: 15344540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spirulina Platensis Attenuates Rebound Dyspeptic Symptoms After Proton Pump Inhibitors' Discontinuation: Phase 2 Placebo-controlled Trial.
    Gronevalt ATM; Bertolin TE; Forcelini CM; Polletto PHM; Pasetti BW; Graeff DB; Rodriguez R; Fornari F
    Altern Ther Health Med; 2024 Feb; 30(2):18-24. PubMed ID: 38401078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
    Miner P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():20-9. PubMed ID: 15496215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Gastroesophageal reflux disease: pathogenetic basis of differentiated tactics of treatment].
    Tkachenko EI; Uspenskiĭ IuP; Karateev AE; Bakulin IG; Pakhomova IG
    Eksp Klin Gastroenterol; 2009; (2):104-14. PubMed ID: 19552028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of Acid in functional dyspepsia.
    Savarino E; Zentilin P; Dulbecco P; Malesci A; Savarino V
    Am J Gastroenterol; 2011 Jun; 106(6):1168; author reply 1168-9. PubMed ID: 21637272
    [No Abstract]   [Full Text] [Related]  

  • 38. [All proton pump inhibitors are equally efficacious in standard dosages].
    Hellström PM; Vitols S
    Lakartidningen; 2003 Jun; 100(25):2212-6. PubMed ID: 12872509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study.
    Kruszelnicka O; Świerszcz J; Bednarek J; Chyrchel B; Surdacki A; Nessler J
    Int J Mol Sci; 2016 Apr; 17(4):454. PubMed ID: 27092494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment.
    Lødrup AB; Reimer C; Bytzer P
    Scand J Gastroenterol; 2013 May; 48(5):515-22. PubMed ID: 23311977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.